Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Actinic Keratosis Treatment Market

Actinic Keratosis Treatment Market Share

Report ID: GMI5859
Published Date: May 2023
Report Format: PDF

Download Free Sample

Actinic Keratosis Treatment Market Share

Major market players operating in the actinic keratosis treatment market include

Sun Pharmaceutical Industries Ltd
Galderma S.A.
Biofrontera AG
Almirall, S.A.

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for actinic keratosis treatment accounted for USD 5.5 billion in 2022 and is estimated to grow at 5.5% CAGR during 2023 to 2032. Rising prevalence of actinic keratosis, coupled with growing demand for minimally invasive procedures is expected to boost the market growth.

The topical medications segment accounted over 49% market share in 2022 and is projected to witness robust growth through 2032, owing to the ability of topical medications to treat multiple AK lesions simultaneously, making them suitable for widespread or field treatment.

North America accounted for 41.6% share in actinic keratosis treatment market in 2022 and is anticipated to grow at considerably over 2023-2032, backed by well-established healthcare infrastructure in the region, along with growing awareness pertaining to various risks associated with sun exposure and regular skin examinations.

Sun Pharmaceutical Industries Ltd, Galderma S.A., Biofrontera AG, Almirall, S.A. among others.